Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

Todd Neale

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

News Daily News

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Yael L. Maxwell

March 09, 2013

News Daily News

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Yael L. Maxwell

March 09, 2013

Presentation

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Presenter: Jessica L. Mega

March 04, 2013

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

Presenter: C. Michael Gibson

October 24, 2012

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

Advertisement

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content